
Citation: Zhongwei Zhao, Xiaoxi Fan, Lili Yang, Jingjing Song, Shiji Fang, Jianfei Tu, Minjiang Chen, Liyun Zheng, Fazong Wu, Dengke Zhang, Xihui Ying, Jiansong Ji. The identification of a common different gene expression signature in patients with colorectal cancer[J]. Mathematical Biosciences and Engineering, 2019, 16(4): 2942-2958. doi: 10.3934/mbe.2019145
[1] | Ahmed Hammad, Mohamed Elshaer, Xiuwen Tang . Identification of potential biomarkers with colorectal cancer based on bioinformatics analysis and machine learning. Mathematical Biosciences and Engineering, 2021, 18(6): 8997-9015. doi: 10.3934/mbe.2021443 |
[2] | Miao Zhu, Tao Yan, Shijie Zhu, Fan Weng, Kai Zhu, Chunsheng Wang, Changfa Guo . Identification and verification of FN1, P4HA1 and CREBBP as potential biomarkers in human atrial fibrillation. Mathematical Biosciences and Engineering, 2023, 20(4): 6947-6965. doi: 10.3934/mbe.2023300 |
[3] | Fang Niu, Zongwei Liu, Peidong Liu, Hongrui Pan, Jiaxue Bi, Peng Li, Guangze Luo, Yonghui Chen, Xiaoxing Zhang, Xiangchen Dai . Identification of novel genetic biomarkers and treatment targets for arteriosclerosis-related abdominal aortic aneurysm using bioinformatic tools. Mathematical Biosciences and Engineering, 2021, 18(6): 9761-9774. doi: 10.3934/mbe.2021478 |
[4] | Yan Li, Yuzhang Zhu, Guiping Dai, Dongjuan Wu, Zhenzhen Gao, Lei Zhang, Yaohua Fan . Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma. Mathematical Biosciences and Engineering, 2020, 17(1): 910-927. doi: 10.3934/mbe.2020048 |
[5] | Lingling Li, Yulu Hu, Xin Li, Tianhai Tian . Mathematical modeling the gene mechanism of colorectal cancer and the effect of radiation exposure. Mathematical Biosciences and Engineering, 2024, 21(1): 1186-1202. doi: 10.3934/mbe.2024050 |
[6] | Kewei Ni, Gaozhong Sun . The identification of key biomarkers in patients with lung adenocarcinoma based on bioinformatics. Mathematical Biosciences and Engineering, 2019, 16(6): 7671-7687. doi: 10.3934/mbe.2019384 |
[7] | Jiaping Wang . Prognostic score model-based signature genes for predicting the prognosis of metastatic skin cutaneous melanoma. Mathematical Biosciences and Engineering, 2021, 18(5): 5125-5145. doi: 10.3934/mbe.2021261 |
[8] | Wei Niu, Lianping Jiang . A seven-gene prognostic model related to immune checkpoint PD-1 revealing overall survival in patients with lung adenocarcinoma. Mathematical Biosciences and Engineering, 2021, 18(5): 6136-6154. doi: 10.3934/mbe.2021307 |
[9] | Tingting Chen, Wei Hua, Bing Xu, Hui Chen, Minhao Xie, Xinchen Sun, Xiaolin Ge . Robust rank aggregation and cibersort algorithm applied to the identification of key genes in head and neck squamous cell cancer. Mathematical Biosciences and Engineering, 2021, 18(4): 4491-4507. doi: 10.3934/mbe.2021228 |
[10] | Qinyan shen, Jiang wang, Liangying zhao . To investigate the internal association between SARS-CoV-2 infections and cancer through bioinformatics. Mathematical Biosciences and Engineering, 2022, 19(11): 11172-11194. doi: 10.3934/mbe.2022521 |
Colorectal cancer (CRC) is one of the leading causes of death associated with cancer worldwide, which has been estimated to cause 50,000 deaths per year in America [1,2]. The pathogenesis of CRC is a complicated process involved in mutations of various oncogenes and tumor suppressor genes that pinpoint multiple cellular events, such as endoplasmic reticulum stress [3], oxidative stress [4], epithelial-mesenchymal transition (EMT) [5], abnormal cell proliferation and apoptosis [6].
Although surgery combined with adjuvant radiotherapy or chemotherapy has effectively improved the prognosis of CRC, metastasis or neoplasm recurrence still occur in more than 50% of the CRC patients who have received a definite diagnosis or underwent intended curative treatment, contributing to a relatively poor 5-year survival rate [7]. Additionally, it is difficult for doctors to achieve early diagnosis of CRC for the reason that specificity of auxiliary examination indices is lacking in clinic, so that many patients may eventually miss the optional chances for surgery, thereby increasing the risk of death [8]. Hence, the detection of early-stage biomarkers and identification of core therapeutic target appear significant to decrease CRC-related deaths.
Recent years, the high-throughput gene microarray has been widely used to screen the differentially expressed genes (DEGs) between normal samples and tumor samples in human beings and animal models, which makes it accessible for us to further explore the entire molecular alterations of tumors at multiple levels involving DNA, RNA, proteins, epigenetic alterations, and metabolism [9,10]. However, it still has a long way to go to put these microarrays in application in clinic because the DEGs identified by gene profiling were countless and the statistical analyses were also too complicated [11]. Therefore, it is urgent to verify a proper number of genes and develop a suitable approach which can be operated by routine assay in clinic.
In this study, we selected the GSE32323 from Gene Expression Omnibus (GEO) and applied bioinformatics analysis to screen the DEGs in CRC. Subsequently, we used STRING to construct the protein-protein interaction (PPI) network to identify the hub genes with top15 degree of connectivity in CRC. Moreover, we made the analysis of these DEGs, including biological process (BP), molecular function (MF), cellular component (CC) and KEGG pathways. We chose top5 up-regulated and top5 down-regulated DEGs to make the overall survival (OS) analysis, aiming to observe the associations between the DEGs and the prognosis of CRC. Finally, we confirmed the mRNA expression level of the top5 up-regulated and top5 down-regulated DEGs by Q-PCR in samples obtained from patients with CRC in our hospital. These genes will assist us to screen and identify significant biomarkers and therapeutic targets of CRC in the near future.
The heading levels should not be more than 4 levels. The fond of heading and subheadings should be 12 point normal Times New Roman. The first letter of headings and subheadings should be capitalized. The gene expression profile of GSE32323 was downloaded from the GEO database, which was a free and publicly available database. 17 pairs of cancer and non-cancerous tissues from patients with CRC in this dataset were detected by Affymetrix HG-U133 Plus 2.0 arrays by Ahmed K [12]. We also downloaded the raw Series Matrix File of GSE32323 from the GEO database.
In our study, the online software GEO2R was employed to analyze the tissue samples in GSE32323 dataset. GEO2R is an online software by which users can divide the samples into two and more groups and select out the DEGs. We used the Benjamini and Hochberg methods by default to discover false rate and used the adjust P value to reduce the errors of false positive. The choice criterion contains the adjust P value < 0.05 and |logFC| ≥ 2.
Gene ontology analysis (GO), serving as a useful approach to annotate genes and gene products, could also identify characteristic biological attributing to high-throughput genome or transcriptome data. Kyoto Encyclopedia of Genes and Genomes (KEGG) is a collection of databases, aiming to handle biological pathways, genomes, diseases, chemical substances and drugs. We divided these DEGs into up-regulated group and down-regulated group. The Database for Annotation, Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/), an online web based on the bioinformatics, is routinely applied for annotating genes and protein function [13]. We input these DEGs separately into DAVID to acquire the GO and KEGG analysis, P < 0.05 as choice criterion. Finally, we used the ImageGP (http://www.ehbio.com/ImageGP/index.php/Home/Index/index.html) to visualize the major biological processes (BP), molecular function (MF) and cell composition (CC) of these DEGs.
GEPIA (http://gepia.cancer-pku.cn/index.html), designed by Chenwei Li, Zefang Tang, and Boxi Kang of Zhang Lab, Peking University, is a newly developed interactive web server aiming at analyzing the RNA sequencing expression data of 9736 tumors and 8587 normal samples from the GTEx and TCGA projects in a standard processing pipeline [14]. In this study, we employed the boxplot to visualize the mRNA expression of top5 up-regulated and top5 down-regulated DEGs in CRC tissues and and normal colorectum tissues. Transcripts per million (TPM) is the number of transcripts from this particular gene normalized first by gene length, and then by sequencing depth (in millions) in the sample. GEPIA also provides the transcripts per million (TPM) of these DEGs to display their relative expression levels.
Similarly, we used the GEPIA database to get the overall survival information of these DEGs. The logrank P value and hazard ratio (HR) with 95% confidence intervals were showed on the plot. P < 0 05 was statistically significant.
We enrolled 15 male patients who were diagnosed with CRC by pathology reports in our hospital. The samples from patients with CRC for the validation of these DEGs were supported by the ethics committee in our hospital. The paired carcinoma and adjacent tissues were firstly isolated. Then total RNA was isolated using the TRIzol (Invitrogen, Carlsbad, CA, USA) kit, the concentrations and purities of which were quantified by an ultraviolet spectrophotometer. The RNA was then reversely transcribed according to the previous literature [15]. The expression levels of top5 up-regulated genes and top5 down-regulated genes were normalized to GAPDH. Relative mRNA expression levels were analyzed by 2-∆∆cycle threshold (CT) method.
Search Tool for the Retrieval of Interacting Genes (STRING) is an online app for evaluating PPI network [16]. For finding the potential correlation of DEGs, we used online app STRING to map the DEGs, subsequently the Cytoscape software was utilized to construct a PPI network. The confidence score ≥ 0.4 and maximum number of interactors = 0 were set as the criterion.
The overall flow diagram of our study is presented in Figure 1. In our study, a total of 17 paired carcinoma and adjacent tissue from patients with CRC were analyzed. We applied the GEO2R online analysis tool with default parameters to screen the DEGs, using adjusted P value < 0.05 and logFC ≤ −2 or logFC ≥ 2 as the cut-off criteria. We captured 451 DEGs including 145 up-regulated DEGs and 306 downregulated DEGs. Whereafter, the DEGs were presented in the form of a heatmap and a volcano plot (Figure 2A-B). In the heatmap, the top25 up-regulated genes and top25 down-regulated genes between carcinoma and adjacent tissue were presented. Among the 451 DEGs, the top5 up-regulated genes involved DPEP1, KRT23, CLDN1, LGR5 and FOXQ1, while the top5 down-regulated genes were CLCA4, ZG16, SLC4A4, ADH1B and GCG. The gene tiles and biological functions of top5 upregulated and top5 down regulated genes were displayed in Table 1.
DEGs | Gene title | Gene symbol | LogFC | Biological function |
Down-regulated | Chloride channel accessory 4 | CLCA4 | 4.91 | Calcium sensitive chloride conductance protein |
Zymogen granule protein 16 | ZG16 | 4.45 | Promoting cell growth and stemness. | |
Solute carrier family 4 member 4 | SLC4A4 | 4.43 | Sodium bicarbonate cotransporter | |
Alcohol dehydrogenase 1B (class I), beta polypeptide | ADH1B | 4.29 | Metabolizing ethanol, retinol, and aliphatic alcohol | |
Glucagon | GCG | 4.15 | Counteracting the action of insulin in the bloodstream. | |
Up-regulated | Dipeptidase 1 | DPEP1 | −4.14 | Kidney membrane enzyme |
Keratin 23 | KRT23 | −4.28 | Intermediate filament proteins | |
Claudin 1 | CLDN1 | −4.46 | Tight junctions | |
Leucine rich repeat containing G protein-coupled receptor 5 | LGR5 | −4.51 | Leucine-rich repeat-containing receptor | |
Forkhead box Q1 | FOXQ1 | −5.55 | Embryonic development and cell cycle regulation |
To ensure the credibility and reliability of the microarray of GSE32323 and get further credible analysis, we re-identified the top5 up-regulated genes and top5 down-regulated genes via Q-PCR. Q-PCR (Figure 5A-B) showed that the mRNA expression levels of DPEP1, KRT23, CLDN1, LGR5 and FOXQ1 were significantly higher in carcinoma group compared with adjacent tissue group (P < 0.05). Meantime, the mRNA expression levels of CLCA4, ZG16, SLC4A4, ADH1B and GCG were obviously down-regulated in carcinoma tissues from patients with CRC (P < 0.05).
To ensure the credibility of the microarray of GSE32323 and proceed further credible analysis, we validated the top5 up-regulated genes and top5 down-regulated genes based on TCGA database via GEPIA. The results showed that the mRNA expression levels of CLCA4, ZG16, SLC4A4, ADH1B and GCG were significantly lower in carcinoma group compared to adjacent tissue group while the mRNA expression level of DPEP1, KRT23, CLDN1, LGR5 and FOXQ1 in carcinoma group were statistically higher than the adjacent tissue group (P < 0.05) (Figure 3A-J). Meanwhile, the TPM analysis demonstrated that the relative expressions of these DEGs were consist with those based on GSE32323 (P < 0.05) (Figure 4A-J).
Furthermore, we analyzed the potential association between the expression levels of top5 upregulated genes as well as top5 downregulated genes and the OS of patients with CRC. The Kaplan-Meier showed that only 1(ZG16) of the 10 genes displayed significantly correlation with the OS of patients with CRC (Figure 6A-J). The high level of ZG16 may contribute to a poorer prognosis of CRC (Logrank p = 0.044, HR = 0.61).
The results (Table2 & Figure 7A-C) from GO term enrichment analysis varied from expression levels and GO classification of the DEGs. By analyzing GO enrichment of these up-regulated and down-regulated DEGs via DAVID, we found that the up-regulated DEGs in BP were mainly enriched in negative regulation of cell proliferation, positive regulation of transcription from RNA polymerase Ⅱ promoter, proteolysis, positive regulation of transcription, DNA-templated and negative regulation of transcription from RNA polymerase Ⅱ promoter while the down-regulated DEGs in BP were mainly concentrated on cell adhesion, negative regulation of cell proliferation, positive regulation of cell proliferation, response to drug and nervous system development. As for CC, the up-regulated DEGs were principally enriched in extracellular region, extracellular space, integral component of plasma membrane, proteinaceous extracellular matrix and cell surface while the down-regulated DEGs were enriched in integral component of membrane, plasma membrane, extracellular exosome, extracellular space and extracellular region. Additionally, MF analysis uncovered that the up-regulated DEGs were mainly enriched in chemokine activity, CXCR chemokine receptor binding, serine-type endopeptidase activity, extracellular matrix binding and Wnt-protein binding while the down-regulated DEGs are responsible for carbonate dehydratase activity, heparin binding, structural constituent of cytoskeleton, hormone activity and zinc ion binding.
Expression | Category | Term | Count | % | P-Value | FDR |
Down-regulated | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 13 | 0.038728513 | 0.013503078 | 19.70156803 |
GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.035749397 | 0.011658571 | 17.24378143 | |
GOTERM_BP_DIRECT | GO:0008284~positive regulation of cell proliferation | 11 | 0.03277028 | 0.07067658 | 69.36458376 | |
GOTERM_BP_DIRECT | GO:0042493~response to drug | 10 | 0.029791164 | 0.014890967 | 21.50558949 | |
GOTERM_BP_DIRECT | GO:0007399~nervous system development | 9 | 0.026812048 | 0.028891454 | 37.69742039 | |
GOTERM_CC_DIRECT | GO:0016021~integral component of membrane | 83 | 0.247266661 | 0.004198766 | 5.157367461 | |
GOTERM_CC_DIRECT | GO:0005886~plasma membrane | 71 | 0.211517264 | 0.001689338 | 2.105290204 | |
GOTERM_CC_DIRECT | GO:0070062~extracellular exosome | 67 | 0.199600798 | 6.59E-08 | 8.30E-05 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 43 | 0.128102005 | 1.82E-08 | 2.29E-05 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 34 | 0.101289957 | 0.002466544 | 3.060090837 | |
GOTERM_MF_DIRECT | GO:0004089~carbonate dehydratase activity | 5 | 0.014895582 | 1.89E-05 | 0.0259938 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 9 | 0.026812048 | 7.38E-04 | 1.012297275 | |
GOTERM_MF_DIRECT | GO:0005200~structural constituent of cytoskeleton | 7 | 0.020853815 | 0.002187539 | 2.974720065 | |
GOTERM_MF_DIRECT | GO:0005179~hormone activity | 6 | 0.017874698 | 0.005649705 | 7.515474579 | |
GOTERM_MF_DIRECT | GO:0008270~zinc ion binding | 25 | 0.07447791 | 0.007595654 | 9.980321245 | |
Up-regulated | GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.072115385 | 4.45E-05 | 0.070505424 |
GOTERM_BP_DIRECT | GO:0045944~positive regulation of transcription from RNA polymerase Ⅱ promoter | 12 | 0.072115385 | 0.047923342 | 54.04862787 | |
GOTERM_BP_DIRECT | GO:0006508~proteolysis | 10 | 0.060096154 | 0.004653246 | 7.118885476 | |
GOTERM_BP_DIRECT | GO:0045893~positive regulation of transcription, DNA-templated | 10 | 0.060096154 | 0.005625306 | 8.544770506 | |
GOTERM_BP_DIRECT | GO:0000122~negative regulation of transcription from RNA polymerase Ⅱ promoter | 10 | 0.060096154 | 0.040288919 | 47.85424336 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 25 | 0.150240385 | 2.24E-05 | 0.026796109 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 23 | 0.138221154 | 1.30E-05 | 0.015593466 | |
GOTERM_CC_DIRECT | GO:0005887~integral component of plasma membrane | 17 | 0.102163462 | 0.0098955 | 11.22182273 | |
GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 10 | 0.060096154 | 3.33E-05 | 0.039831238 | |
GOTERM_CC_DIRECT | GO:0009986~cell surface | 8 | 0.048076923 | 0.044084961 | 41.70407607 | |
GOTERM_MF_DIRECT | GO:0008009~chemokine activity | 6 | 0.036057692 | 1.24E-05 | 0.016078978 | |
GOTERM_MF_DIRECT | GO:0045236~CXCR chemokine receptor binding | 4 | 0.024038462 | 1.86E-05 | 0.024112254 | |
GOTERM_MF_DIRECT | GO:0004252~serine-type endopeptidase activity | 8 | 0.048076923 | 0.00101144 | 1.305200327 | |
GOTERM_MF_DIRECT | GO:0050840~extracellular matrix binding | 3 | 0.018028846 | 0.01109514 | 13.48485303 | |
GOTERM_MF_DIRECT | GO:0017147~Wnt-protein binding | 3 | 0.018028846 | 0.01556121 | 18.42243874 | |
GO: Gene Ontology; FDR: False Discovery Rate. |
To obtain a more comprehensive information regarding to the critical pathways of those selected DEGs, KEGG pathways analysis were also carried out via DAVID. The results in Table3 and Figure 7D disclosed the most vital KEGG pathways of the down-regulated and up-regulated DEGs. The down-regulated DEGs were mainly enriched in mineral absorption, pancreatic secretion, nitrogen metabolism, aldosterone-regulated sodium reabsorption and bile secretion. By contrast, the up-regulated DEGs were mainly responsible for chemokine signaling pathway, pathways in cancer, transcriptional misregulation in cancer, PPAR signaling pathway and rheumatoid arthritis.
Category | Term | Count | % | P-Value | Genes | FDR |
Down-regulatedDEGs | hsa04978:Mineral absorption | 6 | 0.017874698 | 4.69E-04 | TRPM6, MT1M, MT1E, MT1H, MT1X, MT1F | 0.546769342 |
hsa04972:Pancreatic secretion | 6 | 0.017874698 | 0.010495925 | KCNMA1, CLCA1, CLCA4, ATP2A3, CA2, SLC4A4 | 11.59221263 | |
hsa00910:Nitrogen metabolism | 5 | 0.014895582 | 8.18E-05 | CA12, CA7, CA4, CA2, CA1 | 0.095443878 | |
hsa04960:Aldosterone-regulated sodium reabsorption | 5 | 0.014895582 | 0.002219912 | SGK1, NR3C2, HSD11B2, SCNN1G, SCNN1B | 2.561720438 | |
hsa04976:Bile secretion | 5 | 0.014895582 | 0.016846119 | AQP8, SLC51B, CA2, SLC4A4, ABCG2 | 17.99502607 | |
Up-regulatedDEGs | hsa04062:Chemokine signaling pathway | 7 | 0.042067308 | 0.001681492 | CXCL1, PLCB4, PPBP, CXCL5, CXCL3, CXCL8, CXCL11 | 1.951113014 |
hsa05200:Pathways in cancer | 7 | 0.042067308 | 0.053070195 | BMP4, PLCB4, MET, CXCL8, AXIN2, MYC, MMP1 | 47.1893587 | |
hsa05202:Transcriptional misregulation in cancer | 6 | 0.036057692 | 0.005889645 | MET, CXCL8, MMP3, MYC, WT1, PLAU | 6.682415976 | |
hsa03320:PPAR signaling pathway | 4 | 0.024038462 | 0.011041824 | SCD, ACSL6, MMP1, FABP6 | 12.19046418 | |
hsa05323:Rheumatoid arthritis | 4 | 0.024038462 | 0.022861328 | CXCL5, CXCL8, MMP3, MMP1 | 23.72114711 | |
KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: False Discovery Rat |
Applying the STRING online tool, 213 nodes with 264 PPI relationships were found, accounting for about 77.8% of these selected DEGs. According to the degree of connectivity of these DEGs, we constructed the PPI network and selected the top 15 hub genes (Table 4). The top 15 hub genes, possessing high degree of connectivity in CRC are as follows, MYC, CXCR1, TOP2A, CXCL12, SST, TIMP1, SPP1, PPBP, CDK1, THBS1, CXCL1, PYY, LPAR1, BMP2 and MMP3. Among these 15 hub genes: MYC, CXCR1, TOP2A, SPP1, PPBP, CDK1, CXCL1 and MMP3 were significantly up-regulated while CXCL12, SST, TIMP1, THBS1, PYY, LPAR1 and BMP2 significantly down-regulated (P < 0.05). The 15 hub genes could interact with 243 genes directly, and MYC acted as the most intensive gene which could interact with 46 up-regulated genes and 31 down-regulated genes. Intriguingly, among these hub genes, there also displayed very strong interactions (Figure 8).
Gene | Degree of connectivity | Adjusted P value |
MYC | 34 | 9.25E-11 |
CXCR1 | 28 | 1.87E-03 |
TOP2A | 23 | 2.90E-02 |
CXCL12 | 20 | 1.95E-08 |
SST | 18 | 7.36E-09 |
TIMP1 | 17 | 1.05E-02 |
SPP1 | 17 | 3.95E-02 |
PPBP | 17 | 9.73E-04 |
CDK1 | 16 | 1.13E-02 |
THBS1 | 16 | 2.99E-08 |
CXCL1 | 15 | 1.91E-03 |
PYY | 15 | 1.77E-08 |
LPAR1 | 15 | 8.36E-11 |
BMP2 | 15 | 1.06E-05 |
MMP3 | 14 | 7.22E-05 |
CRC is a one of the serious public health problems, which is also being the third most commonly diagnosed cancer and the major factor resulting in cancer-related deaths around the world [17,18]. CRC screening has been demonstrated to greatly decrease the morbidity and the mortality in a great many longstanding or newly economically developed countries [19]. However, at present, there is no an efficient and specific diagnostic methodology and treatment strategy for CRC, which is mainly attributed to the intricate pathogenesis, and its symptoms that are difficult to diagnose in the first several years [20]. Our study mainly focused on the expression profiling selected from microarray studies of CRC. In this study, a total of 17 pairs of cancer and non-cancerous tissues isolated from patients with CRC were analyzed. 451 DEGs including 145 up-regulated DEGs and 306 downregulated DEGs were screened. To obtain a comprehensive understanding of these DEGs, we performed GO function and KEGG pathway analysis.
Our analysis screened 451 DEGs with a quadruple fold change between carcinoma and adjacent tissue from patients with CRC. In our heat map, a total of 50 DEGs including top25 up-regulated genes and top25 down-regulated genes were displayed. From our perspective, these DEGs would be promised to be possible candidates for the diagnosis of CRC in future. Currently, some of these DEGs, in fact, have been already disclosed to be novel indicators of CRC. H Meng et al. [21] found that ZG16 exhibited an extremely high expression in normal epithelial cells from rectum, colon and small intestine in an organ-specific fashion while its protein expression was completely lost in CRC tissues. Furthermore, another study proved that the gene expression and copy number alterations of ZG16 significantly correlated with MLH1 silencing, microsatellite instability (MSI), hyper-mutation status, presence of synchronous adenomas, CpG island methylator phenotype, histological type and gender. Survival analysis showed that patients with higher ZG16 gene expression level displayed longer overall survival and progression-free survival compared with those having relatively lower level. Another study showed that the expression of DPEP1 was strikingly up-regulated in human CRC tissue than that in normal mucosa. Meanwhile, high level of DPEP1 was found to be significantly associated with localisation and histological stage of CRC [22]. Our study screened the DEGs of CRC from the angle of bioinformatics for the first time, however, the clinical practice of these DEGs needs to be further investigated.
In our study, we picked out 15 hub genes of CRC, all of which were located in the core nodes in PPI network, meaning that these genes could be critical therapeutic targets to protect against CRC. For instance, somatostatin (SST), encoding a well-characterized growth-regulatoryand gastrointestinal neuroendocrine peptide, has been proved to be a tumor suppressor gene and own potent anti-tumor effects. SST could suppress tumors through direct and indirect mechanisms. Direct anti-tumor effects involve inhibiting cell proliferation; inducing cell cycle arrest; promoting apoptosis; and suppressing cell invasion while indirect anti-tumor effects are blocking the synthesis and secretion of growth factors as well as growth-promoting hormones, meanwhile stopping angiogenesis which is vital in neoplasm growth and spread [23]. Corroborative evidence has unveiled the decreased protein and mRNA expression of SST in CRC tissues [24]. One of the possible reason contributing to the down-regulation of SST was attributed to the higher SST methylation levels in tumor tissues. As expected, another study showed that pretreatment of demethylation agents into SST methylated CRC cells induced the up-regulation of SST expression in vitro [25]. Clinical research demonstrated that serum methylation level of SST in patients with CRC were obviously predictive of tumor recurrence and cancer-related death [26]. Collectively, our study proved that up-regulating SST in CRC cells may exert potent anti-tumor activity.
An interesting finding of our study was that many DEGs in CRC were related with chemokines and their receptors. To be more specific, GO analysis showed that up-regulated DEGs enriched in MF were mainly responsible for chemokine activity and CXCR chemokine receptor binding. Also, KEGG pathways analysis also disclosed that the up-regulated genes including CXCL1, PLCB4, PPBP, CXCL5, CXCL3, CXCL8, CXCL11 are implicated with chemokine signaling pathway. Additionally, 3 of the top15 hub genes based PPI network were also chemokines and their receptors, namely CXCR1, CXCL12 and CXCL1. Mountainous evidence proved that the interactions between chemokines as well as chemokine receptors could mediate the recruitment of different immune cell subsets into tumour microenvironment where the host immune system and tumour cells could interact [27]. On the one hand, chemokines regulate the molecules affecting tumour immunity as well as therapeutic outcomes in patients [28,29]. On the other one hand, chemokines could also target stromal cells and tumor cells, thereby regulating tumour stemness, angiogenesis [30], proliferation [31], apoptosis [32], and survival [33]. These findings suggested that therapies targeting chemokines in CRC may synergize with current cancer therapies, especially immunotherapies by affecting tumour immunological phenotypes, and improving antitumour immune responses.
In conclusion, we provided a comprehensive and novel analysis of gene expression profiles patients with CRC. Particularly, the top5 down-regulated genes including CLCA4, ZG16, SLC4A4, ADH1B and GCG and the top5 up-regulated genes including DPEP1, KRT23, CLDN1, LGR5 and FOXQ1, which are expected to sensitive biomarkers in diagnosis of CRC. Meanwhile, we also screened the top 15 hub genes involving MYC, CXCR1, TOP2A, CXCL12, SST, TIMP1, SPP1, PPBP, CDK1, THBS1, CXCL1, PYY, LPAR1, BMP2 and MMP3, which could be promising therapeutic targets of CRC. Additionally, genes involved in chemokines pathways were also significantly altered in patients with CRC. Anyway, this analysis may offer the powerful evidence and clues for the future genomic individualized treatment of CRC.
This work was supported by the Science and Technology Project of Zhejiang Province (2014C33147), High-level Talent Project of Lishui City (2016RC29), Zhejiang Province Medical and Health Care Project (2017KY728) and National Natural Science Foundation of China (81803778).
All authors declare no conflicts of interest in this paper.
[1] | K. Yang, F. Zhang, P. Han, et al., Metabolomics approach for predicting response to neoadjuvant chemotherapy for colorectal cancer, Metabolomics, 9 (2018), 110–121. |
[2] | R. L. Siegel, K. D. Miller, S. A. Fedewa, et al., Colorectal cancer statistics, 2017. CA Cancer J. Clin., 3 (2017), 104–117. |
[3] | P. M. Yang, Y. T. Li, C. T. Shun, et al., Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress, Sci. Rep., 11 (2013), 3219.4. S. A. Noonan, M. E. Morrissey, P. Martin, et al., Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment, Oncotarget, 12 (2018), 10536–10548. |
[4] | 5. Y. Liu, G. Wang, Y. Yang, et al., Increased TEADexpression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner, Oncogene, 21 (2016), 2789–2795. |
[5] | 6. A. G. Long, E. T. Lundsmith and K. E. Hamilton, Inflammation and colorectal cancer, Curr. Colorectal Cancer Rep., 4 (2017), 341–3. |
[6] | 7. H. Zheng, L. Yu, S. Luo, et al., miR-29inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4, BMC Cancer, 1 (2017), 140–147. |
[7] | 8. A. Mahasneh, F. Alshaheri and E. Jamal, Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates, Exp. Mol. Pathol., 3 (201, 475–483. |
[8] | 9. N. Li, L. Li and Y. Chen, The identification of core gene expression signature in hepatocellular carcinoma, Oxid. Med. Cell Longev., 4 (201, 1–15. |
[9] | 10. L. Ling, L. Ning, C. He, et al., Proteomic analysis of differentially expressed proteins in kidneys of brain dead rabbits, Mol. Med. Rep., 1 (2017), 215–223. |
[10] | 11. T. Braunschweig, J. Y. Chung, S. M. Hewitt, Tissue microarrays: bridging the gap between research and the clinic, Expert Rev. Proteom., 3 (2005), 325–336. |
[11] | 12. A. Khamas, T. Ishikawa, K. Shimokawa, et al., Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile. Cancer Genom. Proteom., 2 (2012), 67–7513. G. Dennis, B. T. Sherman, D. A. Hosack, et al., DAVID: Database for Annotation, visualization, and Integrated Discovery, Genome Biol., 5 (2003), 3. |
[12] | 14. Z. Tang, C. Li, B. Kang, et al., GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses, Nucleic Acids Res., 1 (2017), 98–102. |
[13] | 15. L. P. Sun, Y. Guo, Y. X. Zhang, et al., Antioxidant and anti-tyrosinase activities of phenolic extracts from rape bee pollen and inhibitory melanogenesis by cAMP/MITF/TYR pathway in B16 mouse melanoma cells, Front. Pharmaco., 176 (2017), 46–51. |
[14] | 16. A. Ikin, C. Riveros, P. Moscato, et al., The Gene Interaction Miner: a new tool for data mining contextual information for protein–protein interaction analysis, Bioinformatics, 2 (2010), 283–284. |
[15] | 17. M. Arnold, M. S. Sierra, M. Laversanne, et al., Global patterns and trends in colorectal cancer incidence and mortality, Gut, 4 (2017), 683–691. |
[16] | 18. D. K. Rex, C. R. Boland, J. A. Dominitz, et al., Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer, Gastroenterology, 7 (2017), 307–323. |
[17] | 19. E. V. Cutsem, A. Cervantes, R. Adam, et al., ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann. Oncol., 8 (2016), 1386–1422. |
[18] | 20. V. P. Deenadayalu and D. K. Rex, Colorectal cancer screening: a guide to the guidelines, Rev. Gasteroenterol. Di., 7 (2016), 204. |
[19] | 21. M. Hui, W. Li, L. A. Boardman, et al., Loss of ZG16 is associated with molecular and clinicopathological phenotypes of colorectal cancer, BMC Cancer, 1 (2018), 433–441. |
[20] | 22. P. A. Eisenach, E. Soeth, C. Röder, et al., Dipeptidase 1 (DPEP1) is a marker for the transition from low-grade to high-grade intraepithelial neoplasia and an adverse prognostic factor in colorectal cancer, Brit. J. Cancer., 3 (3), 694–703. |
[21] | 23. S. Pyronnet, C. Bousquet, S. Najib, et al., Antitumor effects of somatostatin, Mol. Cell Endocrinol., 1 (2008), 230–237. |
[22] | 24. K. Leiszter, F. Sipos, O. Galamb, et al., Promoter Hypermethylation-Related Reduced Somatostatin Production Promotes Uncontrolled Cell Proliferation in Colorectal Cancer, Plos One, 2 (2015), e0118332. |
[23] | 25. Y. Mori, K. Cai, Y. Cheng, et al., A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer, Gastroenterology, 3 (2006), 797–808. |
[24] | 26. Y. Liu, H. C. Min, C. K. Tham, et al., Methylation of serum SST gene is an independent prognostic marker in colorectal cancer, Am. J. Cancer Res., 9 (2016), 2098–3008. |
[25] | 27. N. Nagarsheth, M. S. Wicha and W. Zou, Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy, Nat. Rev. Immunol., 9 (2017), 559–572. |
[26] | 28. H. Verbeke, S. Struyf, G. Laureys, et al., The expression and role of CXC chemokines in colorectal cancer, Cytokine Growth F. R., 5 (2011), 345–358. |
[27] | 29. O. Oladipo, S. Conlon, A. O'Grady, et al., The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue, Br. J. Cancer, 3 (2011),480–487. |
[28] | 30. K. Rupertus, J. Sinistra, C. Scheuer, et al., Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer, Clin. Exp. Metastasis, 4 (2014), 447–459. |
[29] | 31. X. Shen, A. Artinyan, D. Jackson, et al., Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways, Pancreas, 1(2010), 81–87. |
[30] | 32. Y. Fang, F. C. Henderson, Q. Yi, et al., Chemokine CXCL16 expression suppresses migration and invasiveness and induces apoptosis in breast cancer cells, Mediat. Inflamm., 8 (2014), 478641. |
[31] | 33. J. Ehling and F. Tacke, Role of chemokine pathways in hepatobiliary cancer, Cancer Lett., 2 (2016), 173–183. |
1. | John Molinski, Amogha Tadimety, Alison Burklund, John X. J. Zhang, Scalable Signature-Based Molecular Diagnostics Through On-chip Biomarker Profiling Coupled with Machine Learning, 2020, 48, 0090-6964, 2377, 10.1007/s10439-020-02593-y | |
2. | Jing Han, Xue Zhang, Yan Liu, Li Jing, Yi-bing Liu, Li Feng, CLCA4 and MS4A12 as the significant gene biomarkers of primary colorectal cancer, 2020, 40, 0144-8463, 10.1042/BSR20200963 | |
3. | Gong‑Peng Dai, Li‑Ping Wang, Yu‑Qing Wen, Xue‑Qun Ren, Shu‑Guang Zuo, Identification of key genes for predicting colorectal cancer prognosis by integrated bioinformatics analysis, 2019, 1792-1074, 10.3892/ol.2019.11068 | |
4. |
Wei Wang, Jian-Fang Sun, Xiao-Zhong Wang, Hou-Qun Ying, Xia-Hong You, Fan Sun,
A Novel Prognostic Score Based on ZG16 for Predicting CRC Survival , 2020, Volume 13, 1178-7066, 735, 10.2147/PGPM.S275941 |
|
5. | Hossein Hozhabri, Ali Lashkari, Seyed-Morteza Razavi, Ali Mohammadian, Integration of gene expression data identifies key genes and pathways in colorectal cancer, 2021, 38, 1357-0560, 10.1007/s12032-020-01448-9 | |
6. | Li Huang, Xu-Zhi Liang, Yun Deng, Yong-Biao Liang, Xu Zhu, Xiu-Yun Liang, Dian-Zhong Luo, Gang Chen, Ye-Ying Fang, Hui-Hua Lan, Jiang-Hui Zeng, Prognostic value of small nucleolar RNAs (snoRNAs) for colon adenocarcinoma based on RNA sequencing data, 2020, 216, 03440338, 152937, 10.1016/j.prp.2020.152937 | |
7. | Feng Xiao, Jiayu Liu, Yongbo Zheng, Zhen Quan, Wei Sun, Yao Fan, Chunli Luo, Hailiang Li, Xiaohou Wu, The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics, 2020, 0885-3282, 088532822097524, 10.1177/0885328220975249 | |
8. | Ming Tan, Ove B. Schaffalitzky de Muckadell, Maiken Thyregod Joergensen, Gene Expression Network Analysis of Precursor Lesions in Familial Pancreatic Cancer, 2020, 6, 2475-3246, 73, 10.1089/pancan.2020.0007 | |
9. | Tao Wang, Jiandong Fei, Shuangfa Nie, Ajay Goel, Clinicopathologic and prognostic implications of Golgi Phosphoprotein 3 in colorectal cancer: A meta-analysis, 2021, 16, 1932-6203, e0260035, 10.1371/journal.pone.0260035 | |
10. | Giuseppe Agapito, Mario Cannataro, Using BioPAX-Parser (BiP) to enrich lists of genes or proteins with pathway data, 2021, 22, 1471-2105, 10.1186/s12859-021-04297-z | |
11. | Oana-Maria Thoma, Markus F. Neurath, Maximilian J. Waldner, Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment, 2021, 12, 1663-9812, 10.3389/fphar.2021.757120 | |
12. | Ming Li, Ziming Liu, Jia Song, Tian Wang, Hongjie Wang, Yanan Wang, Jiguang Guo, Identification of Down-Regulated ADH1C is Associated With Poor Prognosis in Colorectal Cancer Using Bioinformatics Analysis, 2022, 9, 2296-889X, 10.3389/fmolb.2022.791249 | |
13. | Alba Rodriguez, Luís Antonio Corchete, José Antonio Alcazar, Juan Carlos Montero, Marta Rodriguez, Luis Miguel Chinchilla-Tábora, Rosario Vidal Tocino, Carlos Moyano, Saray Muñoz-Bravo, José María Sayagués, Mar Abad, Dysregulated Expression of Three Genes in Colorectal Cancer Stratifies Patients into Three Risk Groups, 2022, 14, 2072-6694, 4076, 10.3390/cancers14174076 | |
14. | Gabriel Javitt, Alisa Kinzel, Nava Reznik, Deborah Fass, Conformational switches and redox properties of the colon cancer‐associated human lectin ZG16, 2021, 288, 1742-464X, 6465, 10.1111/febs.16044 | |
15. | Tuncay Bayrak, Zafer Çetin, E. İlker Saygılı, Hasan Ogul, Identifying the tumor location-associated candidate genes in development of new drugs for colorectal cancer using machine-learning-based approach, 2022, 60, 0140-0118, 2877, 10.1007/s11517-022-02641-w | |
16. | Pavel Ershov, Stanislav Poyarkov, Yulia Konstantinova, Egor Veselovsky, Anna Makarova, Transcriptomic Signatures in Colorectal Cancer Progression, 2023, 23, 15665240, 239, 10.2174/1566524022666220427102048 | |
17. | Md Abu Horaira, Md. Ariful Islam, Md. Kaderi Kibria, Md. Jahangir Alam, Syed Rashel Kabir, Md. Nurul Haque Mollah, Bioinformatics screening of colorectal-cancer causing molecular signatures through gene expression profiles to discover therapeutic targets and candidate agents, 2023, 16, 1755-8794, 10.1186/s12920-023-01488-w | |
18. | Jan Korbecki, Mateusz Bosiacki, Katarzyna Barczak, Ryta Łagocka, Dariusz Chlubek, Irena Baranowska-Bosiacka, The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers, 2023, 12, 2073-4409, 1406, 10.3390/cells12101406 | |
19. | Karol Bukowski, Beata Marciniak, Mateusz Kciuk, Somdutt Mujwar, Mariusz Mojzych, Renata Kontek, Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides as Novel Potential Anticancer Agents: Apoptosis, Oxidative Stress, and Cell Cycle Analysis, 2023, 24, 1422-0067, 8504, 10.3390/ijms24108504 | |
20. | Seyed Taleb Hosseini, Farkhondeh Nemati, Identification of GUCA2A and COL3A1 as prognostic biomarkers in colorectal cancer by integrating analysis of RNA-Seq data and qRT-PCR validation, 2023, 13, 2045-2322, 10.1038/s41598-023-44459-y | |
21. | Aldona Kasprzak, Agnieszka Adamek, The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management, 2020, 21, 1422-0067, 3494, 10.3390/ijms21103494 | |
22. | Kristin E. Cox, Shanglei Liu, Robert M. Hoffman, Surinder K. Batra, Punita Dhawan, Michael Bouvet, The Expression of the Claudin Family of Proteins in Colorectal Cancer, 2024, 14, 2218-273X, 272, 10.3390/biom14030272 | |
23. | Anastasia Gurinovich, Zeyuan Song, Harold Bae, Anastasia Leshchyk, Mengze Li, Hannah Lords, Stacy L. Andersen, Marianne Nygaard, Kaare Christensen, E. Warwick Daw, Konstantin G. Arbeev, Michael R. Brent, Thomas T. Perls, Paola Sebastiani, SNP rs6543176 is associated with extreme human longevity but increased risk for cancer, 2025, 2509-2723, 10.1007/s11357-024-01478-5 | |
24. | Razieh Heidari, Vahideh Assadollahi, Seyedeh Negar Marashi, Fatemeh Elahian, Seyed Abbas Mirzaei, Cesar Lopez-Camarillo, Identification of Novel lncRNAs Related to Colorectal Cancer Through Bioinformatics Analysis, 2025, 2025, 2314-6133, 10.1155/bmri/5538575 | |
25. | K. Teske, N. A. Erickson, A. Huck, M. Dzamukova, M. Fulde, T. Heinbokel, D. Horst, N. Klymiuk, E. Pastille, A. Mekes-Adamczyk, M. Löhning, A. D. Gruber, R. Glauben, L. Mundhenk, The impact of disease and species differences on the intestinal CLCA4 gene expression, 2025, 0946-2716, 10.1007/s00109-025-02538-9 | |
26. | Sarah E. Glass, Matthew E. Bechard, Zheng Cao, Radhika Aramandla, Ping Zhao, Samuel T. Ellis, Emily H. Green, Elizabeth G. Fisher, Ryan T. Smith, Chelsie K. Sievers, Maria Johnson Irudayam, Frank Revetta, M. Kay Washington, Gregory D. Ayers, Cody N. Heiser, Alan J. Simmons, Yanwen Xu, Yu Wang, Annika Windon, Martha J. Shrubsole, Nicholas O. Markham, Qi Liu, Ken S. Lau, Robert J. Coffey, Dipeptidase-1–knockout mice develop invasive tumors with features of microsatellite-unstable colorectal cancer, 2025, 10, 2379-3708, 10.1172/jci.insight.186938 | |
27. | Gabriel Cutshaw, Elena V. Demidova, Philip Czyzewicz, Elizabeth Quam, Nicole Lorang, AL Warith AL Siyabi, Surinder Batra, Sanjeevani Arora, Rizia Bardhan, Metabolic and proteomic signatures differentiate inflammatory phenotypes from cancer and predict treatment response in patient sera, 2025, 2380-6761, 10.1002/btm2.70029 |
DEGs | Gene title | Gene symbol | LogFC | Biological function |
Down-regulated | Chloride channel accessory 4 | CLCA4 | 4.91 | Calcium sensitive chloride conductance protein |
Zymogen granule protein 16 | ZG16 | 4.45 | Promoting cell growth and stemness. | |
Solute carrier family 4 member 4 | SLC4A4 | 4.43 | Sodium bicarbonate cotransporter | |
Alcohol dehydrogenase 1B (class I), beta polypeptide | ADH1B | 4.29 | Metabolizing ethanol, retinol, and aliphatic alcohol | |
Glucagon | GCG | 4.15 | Counteracting the action of insulin in the bloodstream. | |
Up-regulated | Dipeptidase 1 | DPEP1 | −4.14 | Kidney membrane enzyme |
Keratin 23 | KRT23 | −4.28 | Intermediate filament proteins | |
Claudin 1 | CLDN1 | −4.46 | Tight junctions | |
Leucine rich repeat containing G protein-coupled receptor 5 | LGR5 | −4.51 | Leucine-rich repeat-containing receptor | |
Forkhead box Q1 | FOXQ1 | −5.55 | Embryonic development and cell cycle regulation |
Expression | Category | Term | Count | % | P-Value | FDR |
Down-regulated | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 13 | 0.038728513 | 0.013503078 | 19.70156803 |
GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.035749397 | 0.011658571 | 17.24378143 | |
GOTERM_BP_DIRECT | GO:0008284~positive regulation of cell proliferation | 11 | 0.03277028 | 0.07067658 | 69.36458376 | |
GOTERM_BP_DIRECT | GO:0042493~response to drug | 10 | 0.029791164 | 0.014890967 | 21.50558949 | |
GOTERM_BP_DIRECT | GO:0007399~nervous system development | 9 | 0.026812048 | 0.028891454 | 37.69742039 | |
GOTERM_CC_DIRECT | GO:0016021~integral component of membrane | 83 | 0.247266661 | 0.004198766 | 5.157367461 | |
GOTERM_CC_DIRECT | GO:0005886~plasma membrane | 71 | 0.211517264 | 0.001689338 | 2.105290204 | |
GOTERM_CC_DIRECT | GO:0070062~extracellular exosome | 67 | 0.199600798 | 6.59E-08 | 8.30E-05 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 43 | 0.128102005 | 1.82E-08 | 2.29E-05 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 34 | 0.101289957 | 0.002466544 | 3.060090837 | |
GOTERM_MF_DIRECT | GO:0004089~carbonate dehydratase activity | 5 | 0.014895582 | 1.89E-05 | 0.0259938 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 9 | 0.026812048 | 7.38E-04 | 1.012297275 | |
GOTERM_MF_DIRECT | GO:0005200~structural constituent of cytoskeleton | 7 | 0.020853815 | 0.002187539 | 2.974720065 | |
GOTERM_MF_DIRECT | GO:0005179~hormone activity | 6 | 0.017874698 | 0.005649705 | 7.515474579 | |
GOTERM_MF_DIRECT | GO:0008270~zinc ion binding | 25 | 0.07447791 | 0.007595654 | 9.980321245 | |
Up-regulated | GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.072115385 | 4.45E-05 | 0.070505424 |
GOTERM_BP_DIRECT | GO:0045944~positive regulation of transcription from RNA polymerase Ⅱ promoter | 12 | 0.072115385 | 0.047923342 | 54.04862787 | |
GOTERM_BP_DIRECT | GO:0006508~proteolysis | 10 | 0.060096154 | 0.004653246 | 7.118885476 | |
GOTERM_BP_DIRECT | GO:0045893~positive regulation of transcription, DNA-templated | 10 | 0.060096154 | 0.005625306 | 8.544770506 | |
GOTERM_BP_DIRECT | GO:0000122~negative regulation of transcription from RNA polymerase Ⅱ promoter | 10 | 0.060096154 | 0.040288919 | 47.85424336 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 25 | 0.150240385 | 2.24E-05 | 0.026796109 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 23 | 0.138221154 | 1.30E-05 | 0.015593466 | |
GOTERM_CC_DIRECT | GO:0005887~integral component of plasma membrane | 17 | 0.102163462 | 0.0098955 | 11.22182273 | |
GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 10 | 0.060096154 | 3.33E-05 | 0.039831238 | |
GOTERM_CC_DIRECT | GO:0009986~cell surface | 8 | 0.048076923 | 0.044084961 | 41.70407607 | |
GOTERM_MF_DIRECT | GO:0008009~chemokine activity | 6 | 0.036057692 | 1.24E-05 | 0.016078978 | |
GOTERM_MF_DIRECT | GO:0045236~CXCR chemokine receptor binding | 4 | 0.024038462 | 1.86E-05 | 0.024112254 | |
GOTERM_MF_DIRECT | GO:0004252~serine-type endopeptidase activity | 8 | 0.048076923 | 0.00101144 | 1.305200327 | |
GOTERM_MF_DIRECT | GO:0050840~extracellular matrix binding | 3 | 0.018028846 | 0.01109514 | 13.48485303 | |
GOTERM_MF_DIRECT | GO:0017147~Wnt-protein binding | 3 | 0.018028846 | 0.01556121 | 18.42243874 | |
GO: Gene Ontology; FDR: False Discovery Rate. |
Category | Term | Count | % | P-Value | Genes | FDR |
Down-regulatedDEGs | hsa04978:Mineral absorption | 6 | 0.017874698 | 4.69E-04 | TRPM6, MT1M, MT1E, MT1H, MT1X, MT1F | 0.546769342 |
hsa04972:Pancreatic secretion | 6 | 0.017874698 | 0.010495925 | KCNMA1, CLCA1, CLCA4, ATP2A3, CA2, SLC4A4 | 11.59221263 | |
hsa00910:Nitrogen metabolism | 5 | 0.014895582 | 8.18E-05 | CA12, CA7, CA4, CA2, CA1 | 0.095443878 | |
hsa04960:Aldosterone-regulated sodium reabsorption | 5 | 0.014895582 | 0.002219912 | SGK1, NR3C2, HSD11B2, SCNN1G, SCNN1B | 2.561720438 | |
hsa04976:Bile secretion | 5 | 0.014895582 | 0.016846119 | AQP8, SLC51B, CA2, SLC4A4, ABCG2 | 17.99502607 | |
Up-regulatedDEGs | hsa04062:Chemokine signaling pathway | 7 | 0.042067308 | 0.001681492 | CXCL1, PLCB4, PPBP, CXCL5, CXCL3, CXCL8, CXCL11 | 1.951113014 |
hsa05200:Pathways in cancer | 7 | 0.042067308 | 0.053070195 | BMP4, PLCB4, MET, CXCL8, AXIN2, MYC, MMP1 | 47.1893587 | |
hsa05202:Transcriptional misregulation in cancer | 6 | 0.036057692 | 0.005889645 | MET, CXCL8, MMP3, MYC, WT1, PLAU | 6.682415976 | |
hsa03320:PPAR signaling pathway | 4 | 0.024038462 | 0.011041824 | SCD, ACSL6, MMP1, FABP6 | 12.19046418 | |
hsa05323:Rheumatoid arthritis | 4 | 0.024038462 | 0.022861328 | CXCL5, CXCL8, MMP3, MMP1 | 23.72114711 | |
KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: False Discovery Rat |
Gene | Degree of connectivity | Adjusted P value |
MYC | 34 | 9.25E-11 |
CXCR1 | 28 | 1.87E-03 |
TOP2A | 23 | 2.90E-02 |
CXCL12 | 20 | 1.95E-08 |
SST | 18 | 7.36E-09 |
TIMP1 | 17 | 1.05E-02 |
SPP1 | 17 | 3.95E-02 |
PPBP | 17 | 9.73E-04 |
CDK1 | 16 | 1.13E-02 |
THBS1 | 16 | 2.99E-08 |
CXCL1 | 15 | 1.91E-03 |
PYY | 15 | 1.77E-08 |
LPAR1 | 15 | 8.36E-11 |
BMP2 | 15 | 1.06E-05 |
MMP3 | 14 | 7.22E-05 |
DEGs | Gene title | Gene symbol | LogFC | Biological function |
Down-regulated | Chloride channel accessory 4 | CLCA4 | 4.91 | Calcium sensitive chloride conductance protein |
Zymogen granule protein 16 | ZG16 | 4.45 | Promoting cell growth and stemness. | |
Solute carrier family 4 member 4 | SLC4A4 | 4.43 | Sodium bicarbonate cotransporter | |
Alcohol dehydrogenase 1B (class I), beta polypeptide | ADH1B | 4.29 | Metabolizing ethanol, retinol, and aliphatic alcohol | |
Glucagon | GCG | 4.15 | Counteracting the action of insulin in the bloodstream. | |
Up-regulated | Dipeptidase 1 | DPEP1 | −4.14 | Kidney membrane enzyme |
Keratin 23 | KRT23 | −4.28 | Intermediate filament proteins | |
Claudin 1 | CLDN1 | −4.46 | Tight junctions | |
Leucine rich repeat containing G protein-coupled receptor 5 | LGR5 | −4.51 | Leucine-rich repeat-containing receptor | |
Forkhead box Q1 | FOXQ1 | −5.55 | Embryonic development and cell cycle regulation |
Expression | Category | Term | Count | % | P-Value | FDR |
Down-regulated | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 13 | 0.038728513 | 0.013503078 | 19.70156803 |
GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.035749397 | 0.011658571 | 17.24378143 | |
GOTERM_BP_DIRECT | GO:0008284~positive regulation of cell proliferation | 11 | 0.03277028 | 0.07067658 | 69.36458376 | |
GOTERM_BP_DIRECT | GO:0042493~response to drug | 10 | 0.029791164 | 0.014890967 | 21.50558949 | |
GOTERM_BP_DIRECT | GO:0007399~nervous system development | 9 | 0.026812048 | 0.028891454 | 37.69742039 | |
GOTERM_CC_DIRECT | GO:0016021~integral component of membrane | 83 | 0.247266661 | 0.004198766 | 5.157367461 | |
GOTERM_CC_DIRECT | GO:0005886~plasma membrane | 71 | 0.211517264 | 0.001689338 | 2.105290204 | |
GOTERM_CC_DIRECT | GO:0070062~extracellular exosome | 67 | 0.199600798 | 6.59E-08 | 8.30E-05 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 43 | 0.128102005 | 1.82E-08 | 2.29E-05 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 34 | 0.101289957 | 0.002466544 | 3.060090837 | |
GOTERM_MF_DIRECT | GO:0004089~carbonate dehydratase activity | 5 | 0.014895582 | 1.89E-05 | 0.0259938 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 9 | 0.026812048 | 7.38E-04 | 1.012297275 | |
GOTERM_MF_DIRECT | GO:0005200~structural constituent of cytoskeleton | 7 | 0.020853815 | 0.002187539 | 2.974720065 | |
GOTERM_MF_DIRECT | GO:0005179~hormone activity | 6 | 0.017874698 | 0.005649705 | 7.515474579 | |
GOTERM_MF_DIRECT | GO:0008270~zinc ion binding | 25 | 0.07447791 | 0.007595654 | 9.980321245 | |
Up-regulated | GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.072115385 | 4.45E-05 | 0.070505424 |
GOTERM_BP_DIRECT | GO:0045944~positive regulation of transcription from RNA polymerase Ⅱ promoter | 12 | 0.072115385 | 0.047923342 | 54.04862787 | |
GOTERM_BP_DIRECT | GO:0006508~proteolysis | 10 | 0.060096154 | 0.004653246 | 7.118885476 | |
GOTERM_BP_DIRECT | GO:0045893~positive regulation of transcription, DNA-templated | 10 | 0.060096154 | 0.005625306 | 8.544770506 | |
GOTERM_BP_DIRECT | GO:0000122~negative regulation of transcription from RNA polymerase Ⅱ promoter | 10 | 0.060096154 | 0.040288919 | 47.85424336 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 25 | 0.150240385 | 2.24E-05 | 0.026796109 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 23 | 0.138221154 | 1.30E-05 | 0.015593466 | |
GOTERM_CC_DIRECT | GO:0005887~integral component of plasma membrane | 17 | 0.102163462 | 0.0098955 | 11.22182273 | |
GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 10 | 0.060096154 | 3.33E-05 | 0.039831238 | |
GOTERM_CC_DIRECT | GO:0009986~cell surface | 8 | 0.048076923 | 0.044084961 | 41.70407607 | |
GOTERM_MF_DIRECT | GO:0008009~chemokine activity | 6 | 0.036057692 | 1.24E-05 | 0.016078978 | |
GOTERM_MF_DIRECT | GO:0045236~CXCR chemokine receptor binding | 4 | 0.024038462 | 1.86E-05 | 0.024112254 | |
GOTERM_MF_DIRECT | GO:0004252~serine-type endopeptidase activity | 8 | 0.048076923 | 0.00101144 | 1.305200327 | |
GOTERM_MF_DIRECT | GO:0050840~extracellular matrix binding | 3 | 0.018028846 | 0.01109514 | 13.48485303 | |
GOTERM_MF_DIRECT | GO:0017147~Wnt-protein binding | 3 | 0.018028846 | 0.01556121 | 18.42243874 | |
GO: Gene Ontology; FDR: False Discovery Rate. |
Category | Term | Count | % | P-Value | Genes | FDR |
Down-regulatedDEGs | hsa04978:Mineral absorption | 6 | 0.017874698 | 4.69E-04 | TRPM6, MT1M, MT1E, MT1H, MT1X, MT1F | 0.546769342 |
hsa04972:Pancreatic secretion | 6 | 0.017874698 | 0.010495925 | KCNMA1, CLCA1, CLCA4, ATP2A3, CA2, SLC4A4 | 11.59221263 | |
hsa00910:Nitrogen metabolism | 5 | 0.014895582 | 8.18E-05 | CA12, CA7, CA4, CA2, CA1 | 0.095443878 | |
hsa04960:Aldosterone-regulated sodium reabsorption | 5 | 0.014895582 | 0.002219912 | SGK1, NR3C2, HSD11B2, SCNN1G, SCNN1B | 2.561720438 | |
hsa04976:Bile secretion | 5 | 0.014895582 | 0.016846119 | AQP8, SLC51B, CA2, SLC4A4, ABCG2 | 17.99502607 | |
Up-regulatedDEGs | hsa04062:Chemokine signaling pathway | 7 | 0.042067308 | 0.001681492 | CXCL1, PLCB4, PPBP, CXCL5, CXCL3, CXCL8, CXCL11 | 1.951113014 |
hsa05200:Pathways in cancer | 7 | 0.042067308 | 0.053070195 | BMP4, PLCB4, MET, CXCL8, AXIN2, MYC, MMP1 | 47.1893587 | |
hsa05202:Transcriptional misregulation in cancer | 6 | 0.036057692 | 0.005889645 | MET, CXCL8, MMP3, MYC, WT1, PLAU | 6.682415976 | |
hsa03320:PPAR signaling pathway | 4 | 0.024038462 | 0.011041824 | SCD, ACSL6, MMP1, FABP6 | 12.19046418 | |
hsa05323:Rheumatoid arthritis | 4 | 0.024038462 | 0.022861328 | CXCL5, CXCL8, MMP3, MMP1 | 23.72114711 | |
KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: False Discovery Rat |
Gene | Degree of connectivity | Adjusted P value |
MYC | 34 | 9.25E-11 |
CXCR1 | 28 | 1.87E-03 |
TOP2A | 23 | 2.90E-02 |
CXCL12 | 20 | 1.95E-08 |
SST | 18 | 7.36E-09 |
TIMP1 | 17 | 1.05E-02 |
SPP1 | 17 | 3.95E-02 |
PPBP | 17 | 9.73E-04 |
CDK1 | 16 | 1.13E-02 |
THBS1 | 16 | 2.99E-08 |
CXCL1 | 15 | 1.91E-03 |
PYY | 15 | 1.77E-08 |
LPAR1 | 15 | 8.36E-11 |
BMP2 | 15 | 1.06E-05 |
MMP3 | 14 | 7.22E-05 |